Olivia MillerWhen Pamela Anderson stepped up to receive her Award of Courage at the amfAR Venice Gala on 6 September 2026, she delivered a message that silenced the room: she had been diagnosed with hepatitis C in the late 1990s, told by her doctor that she had just ten years to live. "I'm not a victim," she told the audience. "I'm a victor." Decades after what she called a "death sentence" diagnosis, Anderson is cured — and her story lands at a pivotal moment for Australia, where an estimated 62,880 people are still living with a virus that is now, for most, curable in eight to twelve weeks.
Hepatitis C in Australia: A Disease That Hides in Plain Sight
Hepatitis C is a bloodborne virus that infects the liver. Unlike many conditions, it produces few or no symptoms for years, sometimes decades — which is exactly why Pamela Anderson's situation is so recognisable to specialists. People carry the virus without knowing it, while the liver quietly sustains cumulative damage. Left untreated, chronic hepatitis C can progress to fibrosis, cirrhosis, and ultimately liver cancer.
Australia has made extraordinary progress against the disease. Since the Federal Government listed direct-acting antiviral (DAA) medications on the Pharmaceutical Benefits Scheme (PBS) in March 2016, more than 110,000 Australians have been treated and close to 100,000 have achieved a sustained virological response — the medical definition of cure. That represents a 61 per cent reduction in people living with chronic hepatitis C since 2015, according to data from the Burnet Institute's annual report. Deaths among Australians with hepatitis C have fallen by around 22 per cent over the same period.
And yet, as of the end of 2024, approximately 62,880 Australians remain chronically infected, according to the Australian Government Department of Health and Aged Care. Many of them, like Anderson before her diagnosis, do not know.
The Treatment That Changed Everything
The DAAs listed on Australia's PBS represent one of modern medicine's most significant achievements: a class of antiviral drugs that eliminates hepatitis C from the bloodstream in the vast majority of patients. The key facts are striking in their simplicity.
Treatment is taken as a once-daily pill. It typically runs for eight to twelve weeks, depending on the hepatitis C genotype and the degree of existing liver damage. The medicines are 95 per cent effective overall. Side effects — historically the main deterrent under older interferon-based regimens, which caused severe fatigue, depression, and flu-like symptoms lasting up to a year — are minimal with DAAs. Most patients report little disruption to daily life during their treatment course.
The cost barrier, which once made hepatitis C treatment inaccessible to most patients in Australia (private market prices exceeded $100,000 per course in some countries), has been substantially eliminated. Under the PBS, each 28-day supply of medication costs $7.70 for concession cardholders and up to $47.40 for general patients — and no specialist referral is required for a GP to prescribe DAA treatment. Any registered Australian GP can write the prescription.
In March 2026 — six months before Anderson's speech in Venice — Australia went further. The federal government launched a national telehealth service dedicated to finding and treating the Australians who remain uncured. The service connects patients remotely with GPs and liver health specialists, provides bulk-billed consultations, and coordinates blood test referrals and PBS prescriptions without requiring travel to a major city or hospital.
The Case of Someone Who Didn't Know: A Concrete Scenario
Consider the situation of Mark, a 52-year-old Melbourne plumber who received a blood transfusion after a workplace injury in 1989. Hepatitis C screening of Australia's blood supply was not introduced until February 1992. Mark has no symptoms. His energy levels are normal. A routine blood test five years ago showed slightly elevated liver enzymes, but his GP attributed it to alcohol and didn't order a follow-up hepatitis C test.
Under current Australian clinical guidelines:
- A hepatitis C antibody test: bulk-billed under Medicare — $0 out of pocket
- If the antibody test is positive: a confirmatory HCV RNA test is ordered; if this too is positive, the diagnosis is active infection
- Estimated liver condition: a FibroScan (non-invasive liver stiffness test) at a gastroenterology clinic provides a staging result within 20 minutes; typically bulk-billed or gap of $40–$150
- Treatment: a 12-week course of a standard PBS DAA regimen costs Mark $47.40 per monthly prescription — a total out-of-pocket cost of roughly $142 for the full course
- Outcome probability: a 95 per cent chance of sustained virological response — functional cure — after completing the course
- If Mark had waited another decade with untreated hepatitis C contracted in 1989: he would be 30+ years into chronic infection. At that stage, between 15 and 30 per cent of people have progressed to cirrhosis; of those with cirrhosis, 2–5 per cent develop hepatocellular carcinoma (liver cancer) each year
Mark's window for a straightforward, eight-week cure is still open. A single GP appointment, two blood tests, and a prescription closes it permanently.
Who Should Get Tested — and Why Now
Australian health guidelines recommend hepatitis C testing for anyone with a risk factor. These include:
Blood transfusion or organ transplant before February 1992 — this is the most commonly overlooked risk factor in people over 50. Before screening was introduced, Australia's blood supply was not systematically tested for hepatitis C.
Any history of injecting drug use, even once, even decades ago. Sharing needles, syringes, or even spoons and filters carries transmission risk. Many Australians experimented with drugs in their twenties and have never been tested.
Birth in a high-prevalence country, including parts of South-East Asia, Sub-Saharan Africa, and Eastern Europe, where transmission through medical procedures occurred before modern infection-control standards.
Incarceration — either currently or in the past. Transmission risk is elevated in correctional settings.
Unexplained elevated liver enzymes (ALT or AST) on a routine blood panel. This is frequently the first — and sometimes only — laboratory signal of hepatitis C infection.
Pamela Anderson has not disclosed the exact route of her transmission. She doesn't need to. Her point — that hepatitis C can infect anyone, remain hidden for years, and was once treated as a terminal sentence — is the important one. In Australia in 2026, none of those three things needs to remain true.
When a Specialist Is the Right Call
Most Australians with uncomplicated hepatitis C and no advanced liver disease can be treated directly by their GP. But there are situations where a gastroenterologist or hepatologist — a liver specialist — provides critical value.
If liver damage is suspected or confirmed: If imaging or blood tests suggest fibrosis (scarring) or cirrhosis, a specialist can accurately stage the disease using FibroScan or liver biopsy, and select the most appropriate DAA regimen based on the extent of damage. Some combinations are more effective than others in cirrhotic patients.
If previous DAA treatment did not achieve cure: A small proportion of patients — particularly those with difficult genotypes or who had incomplete treatment adherence — do not achieve SVR on first-line therapy. Re-treatment requires specialist guidance to select alternative combinations.
If significant co-morbidities are present: HIV co-infection, significant kidney disease, or multiple other medications require specialist oversight to manage drug interactions and choose the safest DAA combination.
For monitoring after cure in patients with advanced fibrosis: Once SVR is achieved, liver cancer risk drops substantially but does not return to zero in people who had significant scarring. A hepatologist will typically recommend ongoing annual liver ultrasound monitoring even after the virus is eliminated.
Australia's 2026 national telehealth service now connects patients with specialist expertise remotely, at no additional out-of-pocket cost for most patients. The gap between "I might need a specialist" and "I have an appointment" has never been smaller.
This article contains general health information. It does not constitute medical advice. Speak with a qualified healthcare professional if you have concerns about hepatitis C or liver health.
What Pamela Anderson's Story Can Start for You
Anderson spent years not knowing she carried the virus. Australia's PBS-subsidised testing and 95%-effective treatment mean you don't have to follow the same timeline.
A bulk-billed blood test. A GP consultation. For most people, eight to twelve weeks of once-daily medication. That is the full journey from unknown infection to cure in 2026.
Expert Zoom connects Australians with health specialists who can explain your results, assess your liver health, and guide you through treatment — whether you are in Sydney or a remote community — via video consultation.
